Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVATE: Aclidinium/Formoterol in COPD
NCT02424344Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Primary completion
- Jul 2016
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 4
01
Overview
A Phase 4 trial of aclidinium bromide + formoterol fumarate in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Apr 2015; status: completed.
02
Drugs
aclidinium bromide + formoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02424344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02424344.